Pharmacokinetics and tolerability of single ascending doses of lenalidomide in volunteers

Trial Profile

Pharmacokinetics and tolerability of single ascending doses of lenalidomide in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2013

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 30 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top